Salute e Benessere

Implantica continues to expand in Germany with another reflux Center of…

Dr. Siemssen says, "RefluxStop™ has the potential to improve the lives of countless GERD patients. The innovative RefluxStop™ procedure does not encircle the food passageway which could make it an option for those who weren't previously candidates for surgery. It's rewarding to be able to help a new group of patients seeking relief from the relentless symptoms of GERD with the latest technology represented by RefluxStop™." Dr. Siemssen says, "RefluxStop™ has the potential to…
PR Newswire
06/02/2024

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual…

Dr. Ellis is a highly esteemed expert in the field of allergy and has an extensive research record within anaphylaxis and allergic rhinitis. Dr. Ellis is a highly esteemed expert in the field of allergy and has an extensive research record within anaphylaxis and allergic rhinitis. Robert Rönn, SVP and Head of R&D, said: "We are honoured that the AAAAI program committee selected our OX640 abstract to be presented at this high-profile late breaking oral abstract session. This confirms...
PR Newswire
06/02/2024

Nicox announces presentations at the upcoming Association for Research in Vision…

Press ReleaseNicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 February 6, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024, a key ophthalmology...
Nasdaq GlobeNewswire
06/02/2024

Nordic Bioscience to make its precision medicine biomarker PRO-C3 available in…

"This collaboration will allow faster and broader access to Nordic's precision medicine enabling biomarker PRO-C3. We are very happy to be able to help drug developers in their efforts to bring new drugs for debilitating and deadly chronic diseases to market faster, more cost-efficiently, and in the future, have the potential to improve patients' lives" said Morten A. Karsdal, Chief Executive Officer of Nordic Bioscience. "This collaboration will allow faster and broader access to…
PR Newswire
06/02/2024

Tobacco plain packaging progress continues worldwide with 42 countries and…

The report also features the new Canadian requirement for a warning directly on every individual cigarette. This world precedent setting measure will start to appear on cigarettes in Canada by April 2024. Australia is in progress to become the second country to adopt the measure. progressing The report also features the new Canadian requirement for a warning directly on every individual cigarette. This world precedent setting measure will start to appear on cigarettes inCanadabyApril 2024...
PR Newswire
06/02/2024

Mithra updates on cash position

Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with stakeholdersMithra will present its results for the full year 2023 on 8 March 2024Liege, Belgium, 6 February 2024 – 07:00 CET- Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today provides an update on its current cash position and its plans to address its runway and...
Nasdaq GlobeNewswire
06/02/2024

Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023

Eisai's third quarter financial documents, including presentation material, are available via the following link; https://www.eisai.com/ir/library/settlement/index.html Eisai's third quarter financial documents, including presentation material, are available via the following link;https://www.eisai.com/ir/library/settlement/index.html BioArctic's report for the full year 2023 will be published onFebruary 14at08:00 a.m. CET. This information is information that BioArctic AB...
PR Newswire
06/02/2024

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG…

Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomasPelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement with a well-tolerated safety profile in Phase 3 MANIFEST-2 study, when administered in combination with ruxolitinib in JAK inhibitor-naive MF patients 1 ...
Nasdaq GlobeNewswire
05/02/2024

Innocan Pharma to provide a corporate update via Zoom livestream on February 12…

Registration for the Zoom livestream is available here: https://us06web.zoom.us/meeting/register/tZIlf-2hrzItEtD86WAjjfbFPmtLP_Mq52iJ Registration for the Zoom livestream is availablehere :https://us06web.zoom.us/meeting/register/tZIlf-2hrzItEtD86WAjjfbFPmtLP_Mq52iJ About Innocan Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery...
PR Newswire
05/02/2024

IBA – Transparency Notification

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 5, 2024 18:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification...
Nasdaq GlobeNewswire
05/02/2024

Interim report for the first half of 2023/24 – Correction

ANNOUNCEMENT NO. 250 5 February 2024 Interim report for the first half of 2023/24 – Correction In connection with the previously published interim report for the first half of 2023/24 (announcement no. 249), there were errors in the sales and operating results highlights: EBITDA for the second quarter fell by 36% to DKK 93.1 million, and the EBITDA margin was 48%, compared with 63% in the year-earlier period. EBITDA for the first half fell by 36% to DKK 145.2 million, and the EBITDA...
Nasdaq GlobeNewswire
05/02/2024

Amplity Health Announces Leadership Changes

"Amplity is a high-quality medical and sales engine positioned squarely where the market is heading: the intersection where clinical, medical affairs, and commercial biopharma teams are working tirelessly to accelerate and maximize launch effectiveness and patient access to life-saving oncology, rare disease, and specialty medicines," says Baker, who will also serve on Amplity's Board of Directors. "Amplity is a high-quality medical and sales engine positioned squarely where the…
PR Newswire
05/02/2024

Interim report 2023/24 - Full-year guidance maintained despite continued…

ANNOUNCEMENT NO. 249 5 February 2024Interim report for the first half of 2023/24Full-year guidance maintained despite continued challenging market conditions Rasmus Kofoed, CEO :“Rasmus Kofoed, CEO: “In the second quarter, we saw early signs of market conditions improving within our key market area, cell-based therapy, but the investment climate remains subdued. Our revenue therefore continued to be under pressure, as expected, declining 15% year-on-year to DKK 108.1 million...
Nasdaq GlobeNewswire
05/02/2024

3D Printing Technology is Making it Possible for Each Patient to Get…

Request Exclusive Sample Report: 3D-Printed Dental Brace Industry Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-18891 Request Exclusive Sample Report: 3D-Printed Dental Brace Industry Strategic Insights ,https://www.futuremarketinsights.com/reports/sample/rep-gb-18891 The increasingdemand for personalized orthodontic treatmentplans, technological developments in 3D printing that enable accurate and efficient production, and patient...
PR Newswire
05/02/2024

Court ruling in favor of Safe in its action against Neo Medical

Court ruling in favor of Safe in its action against Neo MedicalEragny-sur-Oise–France – February 5, 2024, 6pm CET. Safe SA (the“Company” ) announces that on January 26, 2024, the Paris Judicial Court found in favor of Safe in its action against Neo Medical SA (Switzerland) and Neo Medical SASU (France) (Neo Medical). As a reminder, Safe took action against Neo Medical before the Paris Judicial Court for infringement of its French patent FR 2 990 840 (the “patent”), unfair...
Nasdaq GlobeNewswire
05/02/2024

Systemair changes Group management

Ulrika comes from ASSA Abloy Global Solutions as Head of M&A and Business Development and has previously worked at AddLife, Sandvik Materials Technology, Swedbank and Telia Company. Ulrika comes from ASSA Abloy Global Solutions as Head of M&A and Business Development and has previously worked at AddLife, Sandvik Materials Technology, Swedbank and Telia Company. - Ulrika has a broad experience in M&A and will contribute with valuable expertise which will be an important asset for...
PR Newswire
05/02/2024

Global Microfluidics Market to Surpass Valuation of $90.26 Billion by 2030…

Request Sample PDF of the Report: https://www.kingsresearch.com/request-sample/microfluidics-market-266 Request Sample PDF of the Report: https://www.kingsresearch.com/request-sample/microfluidics-market-266 Trending Now: Australian Scientists Unveil Innovative Static Droplet Microfluidic Device Enabling Cancer Cell Detection through Simple Blood Tests InSeptember 2023, researchers at the University of Technology (UTS) inSydney, Australia, devised an innovative method for...
PR Newswire
05/02/2024

Recombinant Proteins Market Worth $3.2 Billion | MarketsandMarkets™.

Browse in-depth TOC on "Recombinant Proteins Market" Browse in-depth TOC on "Recombinant Proteins Market" 432 - Tables 43 - Figures 406 - Pages Recombinant Proteins Market Scope: The growth factors and chemokines segment is expected to have the dominant share of the recombinant proteins market in 2023. Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, immune response proteins, structural proteins, membrane...
PR Newswire
05/02/2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2024

Revenues were distributed as follows: Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West Europe :Cyprus,France,Greece,Italy,Luxembourg,Malta,Netherlands,Slovenia,Spain,United Kingdom,Belgium,Ireland,Turkey-The...
PR Newswire
05/02/2024

Rokit Healthcare Scores High Marks in KOSDAQ Tech Listing Evaluation

Already commercially available in around 40 countries including the US, Europe, the Middle East, South America, and Asia, Rokit Healthcare's diabetic foot ulcer treatment technology has demonstrated widespread adoption. The company has demonstrated steady growth, with its annual revenue rising from $5 million in 2021 to $6.9 million in 2022, and a similar or higher growth trend is projected for 2023 and 2024. With the anticipated introduction of medical insurance coverage in the US and the…
PR Newswire
05/02/2024

Curia Receives 2024 CDMO Leadership Award

Curia recognized for its Service in the CDMO industry thyear, the awards are presented by Outsourced Pharma and Life Science Leader. “Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia. “This distinction underscores our commitment to creating value for our customers across all of our R&D and manufacturing offerings, and we are especially appreciative to be acknowledged by the partners we support for that commitment.”Winners of CDMO Leadership Awards are...
Nasdaq GlobeNewswire
05/02/2024

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the…

RIYADH, Saudi Arabia, Feb.05, 2024(GLOBE NEWSWIRE) -- In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite...
Nasdaq GlobeNewswire
05/02/2024

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system…

"VenusP-Valve is able to eliminate pulmonary regurgitation in a wide range of anatomies," said Prof. Lee Benson, Director of Cardiac Diagnostic and Interventional Unit at the Hospital for Sick Children in Toronto, Canada. "Available in different sizes and specifications, the product offers extensive applicability to meet the clinical needs of a larger pulmonary regurgitation patient population." "VenusP-Valve is able to eliminate pulmonary regurgitation in a wide range…
PR Newswire
05/02/2024

Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

Preclinical studies of FZ007-119 have demonstrated high selectivity for JAK1-3, indicating significant potential for clinical benefits, such as improved clinical efficacy and enhanced safety of use. Its exceptional selectivity positions FZ007-119 as a potential Best in Class (BIC) candidate within its category. Preclinical studies of FZ007-119 have demonstrated high selectivity for JAK1-3, indicating significant potential for clinical benefits, such as improved clinical efficacy and enhanced...
PR Newswire
05/02/2024
Altri  Comunicati